Comparison of stroke- and bleed-related healthcare resource utilization and costs among patients with newly diagnosed non-valvular atrial fibrillation and newly treated with dabigatran, rivaroxaban, or warfarin
暂无分享,去创建一个
David M. Smith | A. Gilligan | Xue Song | S. Sander | K. Wilson | J. Franchino-Elder | Cheng Wang | A. Sainski‐Nguyen | C. Henriques